Eli Lilly has announced an 11% fall in their third-quarter sales to $5.4 billion, as generic competition to Zyprexa continued to hurt sales. Net income (GAAP) for the period increased by 7% to $1.3 billion, as the drop in sales was counteracted by a $1.4 billion payment from Bristol-Myers Squibb, as a result of the
Patients in the UK with type II diabetes now have access to a new alternative for managing their blood glucose levels with the launch of Boehringer Ingelheim/Eli Lilly’s new combination drug, Jentadueto, being launched in the UK this week. Jentadueto combines two antiglycaemic therapies – the veteran drug metformin with the dipeptidyl peptidase (DPP)-IV inhibitor
European regulators have given approval to Boehringer Ingelheim and Eli Lilly’s diabetes combo drug, Jentadueto. The pharmaceutical organisations announced earlier today that they received marketing authorisation from the European Commission (EC) for Jentadueto, which combines metformin with the dipeptidyl peptidase (DPP)-IV inhibitor Trajenta (linagliptin) in a single pill. The approval was expected after the European
A new indication for Bristol-Myers Squibb (BMS) and Eli Lilly’s Erbitux, which is sold outside the USA by Merck KGaA, has been approved by US regulators. Meanwhile, the US Food and Drug Administration (FDA) have also cleared the first KRAS companion diagnostic test, the therascreen KRAS diagnostic kit which was developed by the Netherlands-based firm,
The UK’s National Institute for Health and Clinical Excellence (NICE) announced yesterday that they had confirmed in final guidance a endorsement of the use of Eli Lilly’s Bydureon (prolonged-release exenatide) in triple-therapy regimens as a treatment option for people with type 2 diabetes. The director of NICE’s centre for health technology evaluation, Professor Carole Longson,
Although Eli Lilly expects to meet or exceed their current earnings per share guidance for 2011 of $3.84-$3.89, the company has announced that profits for 2012 will be $3.10-$3.20 per share, well below analysts’ estimations. The latter prediction is based on 2012 revenues of $21.8-$22.8 billion, which includes an expected reduction of over $3 billion
In a milestone decision for the pharmaceutical and biotechnology industries, the UK’s Supreme Court yesterday ruled against Eli Lilly and upheld a patent on a gene sequence held by Human Genome Sciences relating to its new GlaxoSmithKline-partnered lupus drug Benlysta. Judge David Hope commented that “the supreme court unanimously allows the appeal … and remits
The UK’s National Institute for Health and Clinical Excellence (NICE) have issued an initial recommendation of approval for the use of Eli Lilly’s Bydureon (exenatide prolonged-release suspension for injection) in triple-therapy options for people with type 2 diabetes, when control of blood glucose remains or becomes inadequate. NICE commented that Bydureon improves glycaemic control in
